Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

Laura Rosiñol, Benjamin Hebraud, Albert Oriol, Anne-Laurène Colin, Rafael Ríos Tamayo, Cyrille Hulin, María Jesús Blanchard, Denis Caillot, Anna Sureda, Miguel Teodoro Hernández, Bertrand Arnulf, Maria-Victoria Mateos, Margaret Macro, Jesús San-Miguel, Karim Belhadj, Juan José Lahuerta, M. Brigid Garelik, Joan Bladé, Philippe Moreau

Open source

DOI: 10.3389/fonc.2023.1197340
Published: 2023-11-02
Container: Frontiers in Oncology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2023.1197340,
  title = {Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma},
  author = {Laura Rosiñol and Benjamin Hebraud and Albert Oriol and Anne-Laurène Colin and Rafael Ríos Tamayo and Cyrille Hulin and María Jesús Blanchard and Denis Caillot and Anna Sureda and Miguel Teodoro Hernández and Bertrand Arnulf and Maria-Victoria Mateos and Margaret Macro and Jesús San-Miguel and Karim Belhadj and Juan José Lahuerta and M. Brigid Garelik and Joan Bladé and Philippe Moreau},
  year = {2023},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2023.1197340},
  url = {https://doi.org/10.3389/fonc.2023.1197340}
}

RIS

TY  - JOUR
TI  - Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
AU  - Laura Rosiñol
AU  - Benjamin Hebraud
AU  - Albert Oriol
AU  - Anne-Laurène Colin
AU  - Rafael Ríos Tamayo
AU  - Cyrille Hulin
AU  - María Jesús Blanchard
AU  - Denis Caillot
AU  - Anna Sureda
AU  - Miguel Teodoro Hernández
AU  - Bertrand Arnulf
AU  - Maria-Victoria Mateos
AU  - Margaret Macro
AU  - Jesús San-Miguel
AU  - Karim Belhadj
AU  - Juan José Lahuerta
AU  - M. Brigid Garelik
AU  - Joan Bladé
AU  - Philippe Moreau
PY  - 2023
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2023.1197340
UR  - https://doi.org/10.3389/fonc.2023.1197340
ER  -

APA

Rosiñol, L., Hebraud, B., Oriol, A., Colin, A., Tamayo, R. R., Hulin, C., Blanchard, M. J., Caillot, D., Sureda, A., Hernández, M. T., Arnulf, B., Mateos, M., Macro, M., San-Miguel, J., Belhadj, K., Lahuerta, J. J., Garelik, M. B., Bladé, J., & Moreau, P. (2023). Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma. Frontiers in Oncology. https://doi.org/10.3389/fonc.2023.1197340

Source records

crossref · retrieved 2026-09-27T01:08:13.228Z